reason report
bottom line yesterday fda approv vertex tripl
combin trikafta treatment cystic fibrosi cf
patient age older least one mutat
approv month earli product clean broad
label without signific safeti toler dose liabil
announc list price year higher
estim expect faster approv clean label higher
price offer revenu earn upsid compar consensu
expect incorpor effect new market
compani model valuat see limit impact revenu
year trajectori like significantli stronger
later year
given higher price excel label updat revenu forecast
higher consensu higher
associ increas price penetr
time trikafta also increas expens significantli
compani clearli ramp invest intern
particularli extern also increas sg cog
forecast modestli oper expens increas
oper margin remain unchang
declin continu forecast
compani reach industry-lead oper margin greater
base chang increas
price target reiter mp rate
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu vertex cf
portfolio loss exclus vertex launch success iter cf
medicin cloud disput price access delay reimburs
europ result success reduct revenu forecast compani
expect vertex cf revenu line grow steadili
compar consensu expect believ vertex geograph revenu mix
continu heavili weight us due continu resist
payer europ dynam put current consensu medium-term revenu estim
risk probabl success tripl combin valuat account
full expect valu cf portfolio well risk-adjust opportun
compani effort antitrypsin defici aatd even posit view dcf
valuat incorpor sustain oper margin requir
consider disciplin compani reput frugal
incorpor premium price target recogn vertex might one
attract larg cap growth asset sector howev view reason
acquisit premium would put compani cost nearli like difficult
pill swallow dilution-avers larg compani
trikafta get broad label treat addit cf patient us
trikafta approv treatment cf patient age year older least one
mutat cftr gene repres total cf patient
importantli approv trikatfa increas address popul vertex medicin
anoth exhibit previous untreat patient one mutat
one minim function mutat het-min frequent seriou diseas
expect rapid adopt trikafta het-min group patient well rapid transit
orkambi symdeko homozyg patient
exhibit cf market address patient drug
safeti profil look larg consist symdeko transaminas elev
clinic trial result product label confirm trikafta carri signific
safeti liabil despit discuss rash lft chang infecti event
black box warn label warn precauti section trikafta
symdeko larg though trikafta label look slightli restrict exhibit
trikafta appear slightli liver toxic risk disclos incid advers
reaction transaminas elev trikafta treat patient vs placebo treat
patient laboratori vial sign abnorm section comparison incid
transaminas elev similar symdeko treat patient placebo accord
symdeko label seriou advers reaction trikafta treat patient margin higher
rate compar placebo rash vs influenza vs overal believ trikafta
secur clean broad label without signific safeti toler dose liabil
exhibit trikafta dosag administr
absolut benefit trikafta sever better symdeko
magnitud benefit trikafta mid-teen exhibit
sever fold better exhibit benefit patient treat symdeko
trikafta take efficaci benefit cf patient whole new level compar symdeko
orkambi addit benefit trikafta also demonstr reduct
pulmonari exacerb pulmonari exacerb event event rate per year
calcul base week per year trikafta group vs placebo group
despit slightli higher liver toxic signal compar symdeko trikafta superior efficaci
profil broader label like prompt convers orkambi/symdeko within year
pend reimburs expect trikafta higher net price low discontinu rate
boost vertex short-term revenu earn upsid
trikaftasymdekodosag administrationshould use patient sever hepat impair use notrecommend patient moder hepat impair unless benefit exce risk reduc dose use patient moder hepat impair liver function test close monitoredreduc dose patient moder sever hepat impair vertex incorpor
exhibit trikafta label absolut chang baselin
exhibit symdeko label absolut chang baselin
earli approv higher price like speed trikafta uptak sale
follow yesterday approv updat cf model vertex compani model
reflect product higher price clean label earli approv acceler trikafta
uptak model revenu forecast doubl increas
peak sale forecast trikafta remain larg unchang
also materi reduc us orkambi symdeko forecast account faster
earlier convers trikafta us orkambi revenu forecast decreas
us symdeko revenu forecast declin
total revenu forecast remain rel unchang trajectori
significantli higher later year given
higher price earlier launch clean broad label updat revenu forecast
higher recent consensu higher oper
expens increas oper margin forecast
remain unchang declin incorpor compani
increas extern invest outlook non-gaap ep forecast increas
continu forecast compani
reach industry-lead oper margin greater base
chang increas price target reiter mp rate stock
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim discount back
year compani cost equiti give valu one year use averag
high growth larg cap biotech price-to-revenu multipl sale
appli revenu estim post-tripl
discount back year compani cost equiti give valu one year
lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kludger iambi compani
main product today risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cf tr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
brand
type event
event trial detail
date known
up/down
expect
ema file cf patient year old
report clinic data peopl two
mutat
evalu abil reduc protein
level urin
svb leerink llc research compani file
million
product sale po adjust
trikata tripl comb ivacaftor tezacaftor elexacaftor approv
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal
current averag growth larg cap biopharma multipl ep nvo azn
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
